Anti-Ro/SSA antibodies in rheumatoid arthritis (RA)

  • F Franceschini1,

    Affiliated with

    • I Cavazzana1,

      Affiliated with

      • F Malacarne1,

        Affiliated with

        • P Airò1,

          Affiliated with

          • R Cattaneo1,

            Affiliated with

            • N Del Papa1,

              Affiliated with

              • A Radice1 and

                Affiliated with

                • RA Sinico1

                  Affiliated with

                  Arthritis Res Ther20035(Suppl 1):8

                  DOI: 10.1186/ar638

                  Published: 24 February 2003

                  Background

                  AntiRo are found in 5–15% of RA. Significant associations were reported with sicca, vasculitis, hypergammaglobulins, ANA, high-titer RF, toxicity to D-penicillamine and gold salts treatment. Aim of the study: to evaluate clinical features, radiologic progression and response to disease-modifying antirheumatic drugs (DMARDs) in antiRo-RA patients.

                  Patients and methods

                  We studied 210 patients with RA: antiRo were determined by CIE, with human spleen extract, and by ELISA with recombinant Ro proteins (Pharmacia). Cutoff values for ELISA were determined testing 177 sera from routine.

                  Results

                  AntiRo were detected in 27 patients (F:M 12.5:1). Two groups (antiRo+ and antiRo-) did not show any difference with regard to disease duration, arthritis onset and articular erosions. AntiRo were associated with xerophthalmia (P < 0.0000001), xerostomia (P = 0.0012), oral ulcers (P = 0.0067), scleritis (P = 0.0067) and amyloidosis (P = 0.042). Rheumatoid factor, antiperinuclear factor and anticitrulline were recorded in 70% in both groups; hypergammaglobulinemia, ANA, anti-dsDNA and AMA were frequently detected in antiRo+ patients. Patients were given a mean of 3.93 DMARDs, with no statistical difference between antiRo+ and antiRo-: hydroxychloroquine, methotrexate and gold salts are the most frequently used. Patients who were antiRo- were more frequently treated with hydroxychloroquine and infliximab, while D-penicillamine was used more frequently in those who were antiRo+. DMARD toxicity was detected in 9.3% of antiRo+, with no statistically significant difference between the two groups.

                  Conclusion

                  AntiRo, found in 12.8% of patients with RA, is associated with extra-articular features and with an autoantibody profile unusual for RA. No difference with respect to DMARD toxicity was found in anti-Ro+ patients.

                  Authors’ Affiliations

                  (1)
                  Piazzale Spedali Civili

                  Copyright

                  © BioMed Central Ltd 2003

                  Advertisement